Bardia A et al. Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC): Final results from the Phase 3 ASCENT study. ASCO 2022;Abstract 1071.
Dombrowski SM et al. Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitor in breast cancer. ASCO 2022;Abstract 1096.
Finn RS et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): Analyses from PALOMA-2. ASCO 2022;Abstract LBA1003.
Giordano J et al. Is there a role for the oncotype DX breast recurrence score genomic assay in estrogen receptor-low positive breast cancer? ASCO 2022;Abstract 564.
Hamilton EP et al. Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress). ASCO 2022;Abstract TPS1108.
Hamilton EP et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. ASCO 2022;Abstract 1000.
Huppert LA et al. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 trial. ASCO 2022;Abstract 504.
Jones RH et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with expanded biomarker analysis. ASCO 2022;Abstract 1005.
Kalinsky K et al. A randomized phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. ASCO 2022;Abstract LBA1004.
Kish JK et al. Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan. ASCO 2022;Abstract 1036.
Krop IE et al. Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress). ASCO 2022;Abstract TPS1111.
Krop IE et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). ASCO 2022;Abstract 1002.
Meisel JL et al. Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). ASCO 2022;Abstract TPS1127.
Metzger O et al. Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance). ASCO 2022;Abstract 505.
Modi S et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients with HER2-low unresectable and/or metastatic breast cancer: Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Pusztai L et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy for early-stage TNBC: Exploratory analysis from KEYNOTE-552. ASCO 2022;Abstract 503.
Rugo HS et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. ASCO 2022;Abstract LBA1001.
Spring L et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial. ASCO 2022;Abstract 512.